| (Values in U.S. Thousands) | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 | Dec, 2019 |
| Sales | 2,458,780 | 1,415,920 | 1,176,280 | 308,870 | 428,210 |
| Sales Growth | +73.65% | +20.37% | +280.83% | -27.87% | +116.03% |
| Net Income | -881,710 | -2,003,820 | -1,413,350 | -1,596,910 | -948,630 |
| Net Income Growth | +56.00% | -41.78% | +11.49% | -68.34% | -40.79% |
Beigene Ltd ADR
(BGNE)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
BeiGene, Ltd. is a biotechnology company which focused on immuno-oncological therapeutics. The company's clinical-stage drug candidates include BGB-3111, BGB-283, BGB-290, and BGB-A317. BeiGene, Ltd. is based in Camana Bay, Cayman Islands.